Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring
Clinical Ultrasound · 31.05.2026 · 11 (1) · 1-18
DOI: 10.18525/cu.2026.11.1.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ultrasound, online erschienen am 31.05.2026. Verfasst von Han Ah Lee und 2 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of the global adult population, and accurate identification of patients with clinically significant fibrosis is critical for risk stratification and therapeutic decision-making. Non-invasive tests (NITs)—encompassing serum-based biomarkers, vibration-controlled transient elastography (VCTE), magnetic resonance elastography, and magnetic resonance imaging-derived proton density fat fraction—have emerged as indispensable tools across the MASLD management continuum. The sequential two-step pathway combining FIB-4 with liver stiffness measurement by VCTE has been validated as the standard framework for fibrosis triage, demonstrating a more than 20-fold gradient in 5-year liver-related event rates between low- and high-risk categories. In the clinical trial setting, NITs have progressively evolved from exploratory secondary endpoints to regulatory co-primary endpoints, culminating in the FDA approvals of resmetirom (2024) and semaglutide (2025) for noncirrhotic metabolic dysfunction-associated steatohepatitis with F2–F3 fibrosis. NIT-based algorithms are now formalized for both patient selection and serial treatment response monitoring, effectively operationalizing a biopsy-sparing treat-and-monitor paradigm in routine clinical practice. Achieving full regulatory acceptance of NIT-only trial designs—requiring prospective validation that NIT-defined response categories predict long-term liver-related outcomes—represents the next critical frontier in MASLD management.
Zitieren
APA
Lee, H. A., Cho, Y. Y., & Kim, H. J. (2026). Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring. Clinical Ultrasound, 11(1), 1-18. https://doi.org/10.18525/cu.2026.11.1.1
Vancouver
Lee HA, Cho YY, Kim HJ. Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring. Clinical Ultrasound. 2026;11(1):1-18. doi:10.18525/cu.2026.11.1.1
BibTeX
@article{Lee2026,
author = {Lee, Han Ah and Cho, Young Youn and Kim, Hyung Joon},
title = {Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring},
journal = {Clinical Ultrasound},
year = {2026},
volume = {11},
number = {1},
pages = {1--18},
doi = {10.18525/cu.2026.11.1.1}
}
EUVIMED